MX2018011425A - Construcciones de anticuerpos de adn y método para utilizarlas. - Google Patents

Construcciones de anticuerpos de adn y método para utilizarlas.

Info

Publication number
MX2018011425A
MX2018011425A MX2018011425A MX2018011425A MX2018011425A MX 2018011425 A MX2018011425 A MX 2018011425A MX 2018011425 A MX2018011425 A MX 2018011425A MX 2018011425 A MX2018011425 A MX 2018011425A MX 2018011425 A MX2018011425 A MX 2018011425A
Authority
MX
Mexico
Prior art keywords
same
antibody constructs
dna antibody
combination
nucleic acid
Prior art date
Application number
MX2018011425A
Other languages
English (en)
Inventor
B Weiner David
Yan Jian
Muthumani Karuppiah
Flingai Seleeke
Sardesai Niranjan
Elliott Sarah
Patel Ami
Original Assignee
B Weiner David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B Weiner David filed Critical B Weiner David
Publication of MX2018011425A publication Critical patent/MX2018011425A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente, se describe una composicion que comprende la combinacion de una secuencia de acido nucleico que codifica un polinucleotido deseado que provoca una respuesta inmunitaria en un mamifero y una secuencia de acido nucleico que codifica un anticuerpo, un fragmento de este, una variante de este, o una combinacion de estos.
MX2018011425A 2016-03-21 2017-03-21 Construcciones de anticuerpos de adn y método para utilizarlas. MX2018011425A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662311316P 2016-03-21 2016-03-21
US201662332381P 2016-05-05 2016-05-05
US201662376162P 2016-08-17 2016-08-17
US201662396748P 2016-09-19 2016-09-19
US201662396750P 2016-09-19 2016-09-19
US201662417093P 2016-11-03 2016-11-03
US201662429473P 2016-12-02 2016-12-02
US201662429454P 2016-12-02 2016-12-02
PCT/US2017/023479 WO2017165460A1 (en) 2016-03-21 2017-03-29 Dna antibody constructs and method of using same

Publications (1)

Publication Number Publication Date
MX2018011425A true MX2018011425A (es) 2019-09-04

Family

ID=59900715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011425A MX2018011425A (es) 2016-03-21 2017-03-21 Construcciones de anticuerpos de adn y método para utilizarlas.

Country Status (11)

Country Link
US (1) US20190091322A1 (es)
EP (1) EP3432918A4 (es)
JP (2) JP2019509350A (es)
KR (2) KR20180138204A (es)
CN (1) CN109890407A (es)
AU (1) AU2017238168A1 (es)
BR (1) BR112018069297A2 (es)
CA (1) CA3018566A1 (es)
MX (1) MX2018011425A (es)
SG (2) SG11201808152PA (es)
WO (1) WO2017165460A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9789175B2 (en) * 2013-03-15 2017-10-17 The Trustees Of The University Of Pennsylvania Synthetic immunogens for prophylaxis or treatment of tuberculosis
AU2017261305A1 (en) * 2016-05-05 2018-12-20 Inovio Pharmaceuticals, Inc. DNA monoclonal antibodies targeting influenza virus
CA3035932A1 (en) * 2016-09-14 2018-03-22 Abbvie Biotherapeutics Inc. Anti-pd-1 antibodies and their uses
US11925685B2 (en) * 2016-09-19 2024-03-12 The Trustees Of The University Of Pennsylvania DNA antibody constructs encoding anti-ZIKV envelope antibodies
WO2018102657A1 (en) * 2016-12-02 2018-06-07 Weiner David B Dna antibody constructs for use against ebola virus
US20200216519A1 (en) * 2017-09-15 2020-07-09 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against ebola virus
WO2019075300A2 (en) * 2017-10-12 2019-04-18 The Wistar Institute Of Anatomy And Biology ANTIGENS MAYARO VIRUS CONSENSUS, DNA TYPE ANTIBODY CONSTRUCTS FOR USE AGAINST THE MAYARO VIRUS, AND THEIR COMBINATIONS
US20210047388A1 (en) * 2018-01-31 2021-02-18 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against ebola virus
WO2019152599A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use
WO2019152603A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against zika virus
US20220298211A1 (en) * 2019-06-04 2022-09-22 Qiang Chen PLANT-PRODUCED mABs AGAINST CHIKUNGUNYA VIRUS WITH ENHANCED EFFECTOR FUNCTION AND EFFICACY
WO2021226343A1 (en) * 2020-05-07 2021-11-11 The Wistar Institute Of Anatomy Andbiology Dna antibody constructs for use against hepatitis b virus
WO2021252519A1 (en) * 2020-06-08 2021-12-16 University Of Florida Research Foundation, Inc. Materials and methods for the diagnosis and treatment of cancer
WO2023183818A2 (en) * 2022-03-21 2023-09-28 University Of Georgia Research Foundation, Inc. A novel h1n1 antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606425D0 (en) * 1996-03-27 1996-06-05 Binding Site Ltd Improvements in and relating to the production of antibodies and test kits incorporating antibodies
CN1480215A (zh) * 2003-07-07 2004-03-10 叶新新 Sars病毒抗原抗体复合疫苗及实验动物模型与方法
JP5744719B2 (ja) * 2008-04-04 2015-07-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法
US20110045534A1 (en) * 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
MX346784B (es) * 2010-11-12 2017-03-31 Inovio Pharmaceuticals Inc Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
EA201591131A1 (ru) * 2012-12-13 2015-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Днк-конструкции антитела и способ их применения
CN105829341A (zh) * 2013-12-13 2016-08-03 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法

Also Published As

Publication number Publication date
EP3432918A1 (en) 2019-01-30
KR20230012070A (ko) 2023-01-25
SG11201808152PA (en) 2018-10-30
JP2019509350A (ja) 2019-04-04
JP2022121440A (ja) 2022-08-19
BR112018069297A2 (pt) 2019-01-22
CN109890407A (zh) 2019-06-14
EP3432918A4 (en) 2020-02-12
US20190091322A1 (en) 2019-03-28
SG10202009182RA (en) 2020-11-27
KR20180138204A (ko) 2018-12-28
WO2017165460A1 (en) 2017-09-28
CA3018566A1 (en) 2017-09-28
WO2017165460A9 (en) 2017-11-09
AU2017238168A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2017006094A (es) Anticuerpos anti-interleucina-33 y sus usos.
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
WO2018035084A8 (en) Monovalent asymmetric tandem fab bispecific antibodies
MX2016013985A (es) Cepas de vacunas de listeria recombinante y metodos para producir las mismas.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MX2016010791A (es) Inmunoterapia con multiples objetivos dirigida por biomarcadores.
MX2019013370A (es) Constructos de anticuerpos de ácidos nucleicos optimizados.
WO2016172551A8 (en) METHODS OF IDENTIFYING BACTERIA COMPRISING BINDING POLYPEPTIDES
MX2016017380A (es) Antagonistas del anticuerpo interferon alfa y omega.
AU2015279552A8 (en) Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2018060368A3 (en) COMPOSITIONS AND METHODS FOR ENHANCING STABILITY OF TRANSGENES IN POXVIRUSES
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.
EA201892124A1 (ru) Днк-конструкции антител и способы их применения
MX2018013521A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.